The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Open accessAbstract
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. Here, we review the recent progress in clinical and basic research into the role of APOE in AD pathogenesis. We also discuss how APOE can be targeted for AD therapy using a precision medicine approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All these effects are consistent with reported roles of APOE4 in inflammation, synaptic impairment, MAPK1 signaling and downstream APP transcription, and early endosomes7,18.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is associated with increased amyloid-β deposition, hyperphosphorylation and aggregation of tau, and accelerated cognitive decline4–7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE4 polymorphism alters the accessibility of the lipid-binding region, which interferes with its cholesterol and lipid transport capacity7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection 1 -5 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“having the APOE ɛ4 coding mutation(s) increases AD risk 3–15 fold [3]”
From Association of SPI1 haplotypes with altered SPI1 gene expression and Alzheimer’s disease risk (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These include PLCG2 P522R rare variant (rs72824905) that provides robust protection against AD (odds ratio ≈ 0.68 [1, 4], comparable to having one APOE2 allele [5]”
From PLCγ2 deficiency compromises systemic immune tolerance and erodes myelin homeostasis while enhancing oxidative metabolism in the mouse brain (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE is the most important risk factor for AD and contributes significantly to the risk of developing several other neurological and nonneurological disorders (18).”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the APOE-E4 allele confers a ∼ 3.7 times greater risk than the common variant, APOE-E3, whereas homozygous APOE-E4/E4 carriers have a ∼12-15 times greater risk for developing AD.”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE genotype is the strongest genetic risk factor for AD21, with APOE ε2 conferring protection from disease and APOE ε4 conferring higher risk, compared to the APOE ε3 allele”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with this, binding to LDLR is required by ApoE to perform its downstream effector function (50–52).”
From Secreted Apoe rewires melanoma cell state vulnerability to ferroptosis (2024) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genome-wide association studies have consistently implicated immune-related pathways in AD susceptibility, particularly those involving microglial function [21,22].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When activated, microglia, the resident immune cells of the central nervous system, play a central role in amyloid clearance, synaptic remodeling, and the regulation of inflammatory signaling within the brain [21].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE gene is a known genetic risk factor for neurodegeneration and cardiovascular disease (CVD) [1, 2].”
From Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 exacerbates amyloid pathology by promoting Aβ production and aggregation, and inhibiting Aβ clearance and degradation”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 aggravates the tau pathology via promoting tau phosphorylation, aggregation, propagation, and tau-mediated neurodegeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 mediates and regulates the endocytosis of > 30 ligands, including apolipoprotein E (APOE) and amyloid-β (Aβ) [21–27]”
From LRP1 is a neuronal receptor for α-synuclein uptake and spread (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Compared with APOE3, the APOE4 isoform increases AD risk and theAPOE2 isoform reduces AD risk.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 isoform may affects the development and progression of AD through multiple different pathways in which inflammatory regulation plays crucial role.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“It is known that APOE is predominantly expressed in glial cells, particularly astrocytes and activated microglia, which play central roles in A β accumulation, clearance, and neuroin fl ammation 3,4 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Hyperphosphorylated forms of the microtubule-associated protein tau in neurons is a major hallmark of AD [2, 3].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Multiple cohort studies have demonstrated that the APOE ε4 allele is a major genetic risk factor for AD”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“while the three common isoforms (APOE2, APOE3, and APOE4) influence both amyloid‐β–dependent and independent pathways implicated in AD pathogenesis [1, 2].”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“APOE plays a crucial role in the pathophysiology of AD, particularly in relation to Aβ and tau.43,44”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Cerebrovascular dysfunction has been recognized as a major pathological process of AD”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
The cited source says what the claim attributes to it.
In the citing paper
“with ApoE4-positive cells showing reduced function (Rawat et al., 2019; Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“ApoE4 shows both loss-of-function and gain-of-toxic-function across various AD pathogenesis pathways (Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, cerebral glucose hypometabolism occurs in both the early stage of AD (Christian et al., 2020; Yamazaki et al., 2019) and epilepsy (McDonald et al., 2018; Patel, 2018).”
From APOE4 reduces hippocampal expression of phosphoglycerate kinase 1 and sodium potassium pump to enhance seizure susceptibility in mice (2026) · cites this paper as Yamazaki et al., 2019
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“We also found that LECs isolated from the meninges of 6-month-old 5xFAD mice showed significant changes in the expression of genes involved in processes such as exocytosis, phospholipase D signaling, and response to low-density lipoprotein (Extended Data Fig. 1f–k), suggesting that meningeal Aβ deposition might affect meningeal LECs early on through deleterious processes previously implicated in”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a specific ApoE4 fragment, ApoE4[Δ(166-299)], has previously been found to promote the cellular uptake of extracellular Aβ42 and resulted in increased oxidative stress [28], similar to the effect of L28P.”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“APOE is the most significant known risk factor for sporadic Alzheimer’s disease”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“ApoE4 exhibits the strongest receptor binding and is considered a high-risk allele, while ApoE2 exhibits the weakest receptor binding and is considered protective (Yamazaki et al., 2019).”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“APOE also affects tau pathogenesis and tau-mediated neurodegeneration [468].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [468]
In the citing paper
“In fact, 39 AD-associated genes were found within the 10th percentile of highly expressed genes in meningeal LECs, including Apoe, which is intrinsically linked to altered risk for late onset AD15,31 and was one of the few highly expressed genes found at the intersection between all three cell types (Extended Data Fig. 9o).”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Self-citation
Cited by
Sorted by citations
Items 801–900 of 1,006
Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
Guo, M. H., & Vaishnavi, S. (2023) · Current Treatment Options in Neurology · doi:10.1007/s11940-023-00750-x · Cited by 6
Efraimidis, E., Krokidis, M. G., Exarchos, T. P., Lázár, T., & Vlamos, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713543 · Cited by 7
Investigation into the vascular contributors to dementia and the associated treatments
Davidson, C. G., Woodford, S. J., Mathur, S., Valle, D., Foster, D. T., Kioutchoukova, I. P., Mahmood, A., & Lucke-Wold, B. P. (2023) · Exploration of neuroscience · doi:10.37349/en.2023.00023 · Cited by 6
Kim, J., Kim, S., Um, Y. H., Wang, S., Kim, R. E. Y., Choe, Y. S., Lee, J., Kim, D., Lim, H. K., Lee, C. U., et al. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1113 · Cited by 6
Su, C., Zhang, J., & Zhao, H. (2023) · Journal of the American Statistical Association · doi:10.1080/01621459.2023.2297467 · Cited by 6
CRISPR Advancements in Correcting Protein Misfolding: Implications for Neurodegenerative Disorders
Aslam, A., Kumar, D. J. S., Yadav, K., Yadav, A., & Ahmad, R. (2024) · Gene Expression · doi:10.14218/ge.2024.00002 · Cited by 6
Yang, L. T., Anthony, G., & Kaufer, D. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197549469.003.0028 · Cited by 6
Wijesinghe, P., Li, H. R., Ai, Z., Campbell, M., Chen, S. X., Xi, J., Pham, W. N., & Matsubara, J. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1495615 · Cited by 6
Multivariate proteome-wide association study to identify causal proteins for Alzheimer disease
Fang, L., Xue, H., Lin, Z., & Pan, W. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.12.010 · Cited by 6
Trompeta, C., Gasca‐Salas, C., Rodríguez‐Rojas, R., Fernández‐Rodríguez, B., Clarimón, J., García‐Cañamaque, L., Guida, P., Hernández‐Fernández, F., Sánchez‐Juan, P., Olazarán, J., et al. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.123510 · Cited by 6
Romano, R. R., Carter, M. A., Dietrich, M. S., Cowan, R. L., Bruehl, S. P., & Monroe, T. B. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201293 · Cited by 6
Deng, S., Sun, L., Chen, W., Liu, X., & Chen, S. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s342673 · Cited by 6
iTRAQ-Based Proteomic Analysis of APP Transgenic Mouse Urine Exosomes
Zhou, X., Sheikh, A. M., Matsumoto, K., Mitaki, S., Shibly, A. Z., Zhang, Y., Garu, A., Yano, S., & Nagai, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010672 · Cited by 6
Kessler, K., Giannisis, A., Bial, G., Foquet, L., Nielsen, H. M., & Raber, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-28165-3 · Cited by 6
Advances in the Study of APOE and Innate Immunity in Alzheimer’s Disease
Li, Y., Chang, J., Chen, X., Liu, J., & Zhao, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230179 · Cited by 6
Zhai, T., Krass, E., Zhang, F., & Huang, Z. J. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1188430 · Cited by 6
Bibliometric analysis of global research on the role of apolipoprotein E in Alzheimer's disease
Wang, Z., Zhu, X., Wen, Y., & Shang, D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17987 · Cited by 6
Rai, A., Ojiakor, O. A., & Rylett, R. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15904 · Cited by 6
Mosaic loss of the Y chromosome in human neurodegenerative and oncological diseases
Kuznetsova, I. L., Uralsky, L. I., Tyazhelova, T. V., Андреева, Т. В., & Рогаев, Е. И. (2023) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vjgb-23-61 · Cited by 6
Takebayashi, Y., Yamazaki, Y., Yamada, H., Yazawa, K., Nakamori, M., Kurashige, T., Morino, H., Takahashi, T., Sotomaru, Y., & Maruyama, H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.10.038 · Cited by 6
Self-citationKashtanova, D. A., Мамчур, А. А., Dzhumaniyazova, I. H., Ivanov, M. V., Erema, V. V., Zelenova, Е., Yakovchik, A., Gusakova, M., Rumyantseva, A. M., Terekhov, M. V., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1273825 · Cited by 6
Yamada, H., Yamazaki, Y., Takebayashi, Y., Yazawa, K., Sasanishi, M., Motoda, A., Nakamori, M., Morino, H., Takahashi, T., & Maruyama, H. (2024) · Scientific Reports · doi:10.1038/s41598-023-50941-4 · Cited by 6
Self-citationKim, R., Park, S., Yoo, D., Suh, Y. J., Jun, J., & Jeon, B. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202288 · Cited by 6
Exploring the Genetic Associations Between the Use of Statins and Alzheimer's Disease
Lee, J., Park, S., Kim, Y., Kim, H. M., & Oh, C. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.2.133 · Cited by 6
Applications of 3D printing in aging
Ma, M., Gu, J., Wang, D., Bi, S., Liu, R., Zhang, X., Yang, J. Y., & Zhang, Y. (2023) · International Journal of Bioprinting · doi:10.18063/ijb.732 · Cited by 6
Hou, X., Heckman, M. G., Fiesel, F. C., Koga, S., Soto‐Beasley, A. I., Watzlawik, J. O., Zhao, J., Valentino, R. R., Johnson, P. W., White, L. J., et al. (2023) · medRxiv · doi:10.1101/2023.10.16.23297100 · Cited by 6
Self-citationAssociation of rare APOE missense variants with Alzheimer's disease in the Japanese population
Miyashita, A., Obinata, A., Hara, N., Mitsumori, R., Kaneda, D., Hashizume, Y., Sano, T., Takao, M., Gabdulkhaev, R., Tada, M., et al. (2025) · Journal of Alzheimer’s Disease · doi:10.1177/13872877251340710 · Cited by 5
A multimodal Neuroimaging-Based risk score for mild cognitive impairment
Zendehrouh, E., Sendi, M. S. E., Abrol, A., Batta, I., Hassanzadeh, R., & Calhoun, V. D. (2024) · NeuroImage Clinical · doi:10.1016/j.nicl.2024.103719 · Cited by 5
Parishin A ameliorates cognitive decline by promoting PS1 autophagy in Alzheimer’s disease
Guo, S., Yi, L., Luo, M., Dong, Z., & Du, Y. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1516190 · Cited by 5
Tian, W., He, S., Zhong, S., Wang, M., Yingting, L., Sun, J., Wang, G., Li, X., & Chen, H. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c02367 · Cited by 5
A Review on the Pathophysiology of Alzheimer’s Disease
Agarwal, U., Kapoor, G. T., & Tonk, R. K. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037416859250915091846 · Cited by 5
Yang, Y., He, S., Lin, Y., Chen, J., Yang, R., Li, X., Sun, J., Wang, G., Tian, W., & Chen, H. (2025) · Phytochemistry · doi:10.1016/j.phytochem.2025.114712 · Cited by 5
Zhang, Q., Long, S., Zhang, N., Sun, G., Zhao, L., & Zhong, R. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117637 · Cited by 5
Modeling neurovascular dysfunction in Alzheimer’s disease using an isogenic brain-chip model
Shen, A. N., Matazel, K. S., Gill, W. D., Ewart, L. C., Daughters, R. S., & Rosas-Hernández, H. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00708-y · Cited by 5
Advances in Alzheimer’s disease: mechanistic insights and therapeutic targets
Jia, Y.-J., Ge, Y., Li, B., Yang, Y., Chen, H., Liu, J., Guo, J., Yu, J., Ye, K., Wang, J., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-2991-7 · Cited by 6
Ge, J., Ge, J., Bao, M., Zhang, L., Li, K., Ji, A., Mao, X., Jiang, X., Yue, K., Sun, J., et al. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103069 · Cited by 5
Kang, J., Zhang, C., Wang, Y., Peng, J., Berger, B., Perrimon, N., & Shen, J. (2023) · Genetics · doi:10.1093/genetics/iyad202 · Cited by 5
ApoE maintains neuronal integrity via microRNA and H3K27me3-mediated repression
Tan, J., Tan, Y.-Y., Ngian, Z., Chong, S. Y., Rao, V. K., Wang, J., Zeng, X., & Ong, C. (2024) · iScience · doi:10.1016/j.isci.2024.109231 · Cited by 5
APOE ε4 carriage associates with improved myocardial performance from adolescence to older age
Topriceanu, C., Shah, M., Webber, M. R., Chan, F., Shiwani, H., Richards, M., Schott, J. M., Chaturvedi, N., Moon, J., Hughes, A. D., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03808-z · Cited by 5
Generation of novel anti‐apo E monoclonal antibodies that selectively recognize apo E isoforms
Ohgita, T., Sakai, K., Fukui, N., Namba, N., Nakano, M., Kiguchi, Y., Morita, I., Oyama, H., Yamaki, K., Nagao, K., et al. (2024) · FEBS Letters · doi:10.1002/1873-3468.14858 · Cited by 5
Chen, A. M., Gajdošík, M., Ahmed, W., Ahn, S., Babb, J. S., Blessing, E., Boutajangout, A., de Leon, M. J., Debure, L., Gaggi, N. L., et al. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120742 · Cited by 5
Susceptible Genes and Polymorphisms Associated with Communicable and Noncommunicable Diseases
Olaniyan, M. F., Oladele, A. S., Tijani, A. W., Muhibi, M. A., & Olaniyan, T. B. (2024) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0001 · Cited by 5
Tristão‐Pereira, C., Fuster, V., López‐Jiménez, A., Fernández‐Pena, A., Semerano, A., Fernandez‐Nueda, I., García‐Lunar, I., Ayuso, C., Sánchez‐Gonzalez, J., Ibáñez, B., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.09.028 · Cited by 5
Unraveling APOE4's Role in Alzheimer's Disease: Pathologies and Therapeutic Strategies
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037326839241014054430 · Cited by 5
Qin, S.-J., Zeng, Q.-G., Zeng, H.-X., Zeng, H.-X., Wu, Q.-Z., Lv, Y., Dai, J., Dong, G., & Zeng, X. (2025) · Environmental Pollution · doi:10.1016/j.envpol.2024.125601 · Cited by 6
Hudák, A., & Letoha, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094037 · Cited by 5
Influence of APOE locus on poor prognosis of COVID-19
Rodrigues, J. C. G., Pinto, P., Leitão, L. P. C., Vinagre, L. W. M. S., Monte, N., Fernandes, M. R., Khayat, A. S., de Assumpção, P. P., dos Santos, N. P. C., & dos Santos, S. E. B. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e07379 · Cited by 5
Role of astrocytes in Alzheimer's disease pathogenesis and the impact of exercise-induced remodeling
Shao, J., Deng, Q., Feng, S., Wu, C., Liu, X., & Yang, L. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150418 · Cited by 5
Wu, Q. Y., Geng, Z., Lu, J., Wang, S., Yu, Z., Wang, S., Ren, X., Guan, S., Liu, T., & Chen, Z. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1467562 · Cited by 5
Therapeutic considerations for APOE and TOMM40 in Alzheimers disease: A tribute to Allen Roses MD
Sabbagh, M. N., Pope, E. D., Cordes, L., Shi, J., & Decourt, B. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1849138 · Cited by 5
Aggregate Trends of Apolipoprotein E on Cognition in Transgenic Alzheimer’s Disease Mice
Watson, Y., Nelson, B., Kluesner, J. H., Tanzy, C., Ramesh, S., Patel, Z., Kluesner, K. H., Singh, A., Murthy, V., & Mitchell, C. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210492 · Cited by 5
El-Ganainy, S. O., Cijsouw, T., Ali, M. A., Schoch, S., & Hanafy, A. S. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2022.2056446 · Cited by 5
Apolipoprotein E4 inhibits γ‐secretase activity via binding to the γ‐secretase complex
Sun, Y., Islam, S., Gao, Y., Nakamura, T., Zou, K., & Michikawa, M. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15750 · Cited by 5
Luckett, E. S., Schaeverbeke, J. M., Meyer, S. D., Adamczuk, K., Laere, K. V., Dupont, P. J., & Vandenberghe, R. R. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103321 · Cited by 5
Role of white matter hyperintensity in effects of apolipoprotein E on cognitive injury
Raber, J., & Silbert, L. C. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1176690 · Cited by 5
Panigrahy, S., Sikder, A., Amulya, E., Shah, S., Khairnar, P., Saraf, S., & Srivastava, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105325 · Cited by 5
O Estilo de Vida dos Muito Idosos Importa
Cesena, F. Y. (2020) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20200586 · Cited by 5
Lu, W., Kawatani, K., Ren, Y., Nambara, T., Jia, L., Jeevaratnam, S., Lee, E., Martinez, P. R., Izhar, T., Wang, N., et al. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-01982-0 · Cited by 4
Self-citationFan, Y., Wang, X., Ling, Y., Wang, Q., ZHOU, X., Li, K., & ZHOU, C. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108475 · Cited by 4
He, Z., Nie, Y., Zhang, W., Liu, Y., Liu, Y., Xue, H., Ai, S., Feng, H., Zhou, Y., Zhang, J., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251344253 · Cited by 4
Dou, D., Lu, J., Chen, X., & Zhang, X. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03931-2 · Cited by 4
Yuan, X., Gao, L., Peng, Y., She, T., & Wang, J. (2025) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2025.103301 · Cited by 4
CSF pTDP-43 across the Alzheimer's spectrum: Links to amyloid, APOE and vasculopathy
Rafiee, Z., Pocevičiūtė, D., Santiago, J., Mahmoud, R., Janelidze, S., Hansson, O., & Wennström, M. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107193 · Cited by 4
Kim, B.-G., Yuk, M., Park, M., Ryu, H., Park, J., Yu, H., Park, S. S., Hong, J. T., Lim, K., Han, S., et al. (2025) · Brain · doi:10.1093/brain/awaf244 · Cited by 4
MtDNA‐depleted neuronal cell transcriptomes reveal Alzheimer's disease‐related changes
Menta, B. W., Schueddig, E., Ranjan, A., Li, Y., Andrews, S. J., Wilkins, H., Pei, D., & Swerdlow, R. H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70929 · Cited by 4
Bhat, S. S., Niranjan, V., Chandran, T. R., Kulkarni, S. R., Makkar, S., Dixit, V., Subhasa, C. K., & Vishal, A. (2025) · Advances in Biomarker Sciences and Technology · doi:10.1016/j.abst.2025.12.004 · Cited by 4
Delivanoglou, N., Todd, K. T., Almeida, F., Rego, S., Changavi, A., Spajer, M., Ayuso, V. E., Pinho-Correia, L. M., Sánchez, G., das Neves, S. P., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.02.030 · Cited by 5
Self-citationUwisengeyimana, J. D. D., Wang, Y., Nguchu, B. A., Wang, X., & Qiu, B. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120435 · Cited by 4
Lin, G., He, Q., Cai, J., Yang, X., & Wang, Y. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.109954 · Cited by 4
TIMely connections: APOE4, aging, and Alzheimer’s
Li, Q. (2024) · Immunity · doi:10.1016/j.immuni.2023.12.015 · Cited by 4
Cammisuli, D. M., Tuena, C., Riva, G., Repetto, C., Axmacher, N., Chandreswaran, V., Isella, V., Pomati, S., Zago, S., Difonzo, T., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14020192 · Cited by 4
Peng, K. Y., Liemisa, B., Pasato, J., D’Acunzo, P., Pawlik, M., Heguy, A., Penikalapati, S. C., Labuza, A., Pidikiti, H., Alldred, M. J., et al. (2024) · Traffic · doi:10.1111/tra.12937 · Cited by 4
Yao, Z., Wang, J., Zhang, T., Ai, H., Abdelrahman, Z., Wu, X., Wang, D., Chen, F., Zhang, Z., Wang, X., et al. (2024) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2024.100313 · Cited by 4
Zhao, B., Zang, P., Quan, M., Wang, Q., Guo, D., Jia, J., & Wang, W. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70202 · Cited by 4
Unveiling FOXO3's metabolic contribution to menopause and Alzheimer's disease
O'Mahony, C., Hidalgo‐Lanussa, O., & Barreto, G. E. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112679 · Cited by 3
Differences in the lifetime risk and population burden of dementia
(2025) · Nature Medicine · doi:10.1038/s41591-024-03457-x · Cited by 4
Zeng, F., Tiwari, S., Chok, A., Zhou, Y., Zhao, Y., Chen, X., Hao, Y., Zhu, K., Kettenmann, H., & Xiang, X. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.07.013 · Cited by 4
Communicating the risk of dementia: a scoping review
Swirska, M., Laurell, A. A. S., Sidhom, E., Pizzol, D., Smith, L., & Underwood, B. R. (2025) · BMJ Neurology Open · doi:10.1136/bmjno-2025-001138 · Cited by 4
Im, M., Klymenko, O. О., Gonchar, O. O., Karasevich, N. V., & In, K. (2023) · Neurophysiology · doi:10.1007/s11062-025-09958-w · Cited by 4
Recent Advances and Future Directions in Alzheimer’s Disease Genetic Research
Stancheva, M., Toncheva, D. I., & Karachanak-Yankova, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167819 · Cited by 4
Exploring efficient and effective mammalian models for Alzheimer’s disease
Kayano, M. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1652754 · Cited by 4
Kim, C., Son, K. J., Lee, J. H., & Kim, J. H. (2021) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2021.104418 · Cited by 4
Kapan, A., Haider, S., Wakolbinger, M., & Spatt, J. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13862 · Cited by 4
Guan, Y., Cheng, C. H., Bellomo, L. I., Narain, S., Bigornia, S., Garelnabi, M., Scott, T. M., Ordovás, J. M., Tucker, K. L., Bhadelia, R. A., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1285333 · Cited by 4
Wu, C., Ling, N., Vieu, P., & Fan, G. (2024) · Test · doi:10.1007/s11749-024-00946-6 · Cited by 4
Human induced pluripotent stem cell models for Alzheimer’s disease research: a bibliometric analysis
Sun, Y., Liu, Z., Zhang, Z., Kang, Y., Wang, X., Zhang, Y., Liu, Y., & Zhao, P. (2025) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2025.1548701 · Cited by 4
Metabolic control of microglia in health and disease
Colombo, G., Monsorno, K., & Paolicelli, R. C. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19104-6.00009-7 · Cited by 4
Variations of global brain asymmetry are associated with aging and related diseases
Hu, H., Guo, D., Pu, Y., Abuduaini, Y., Wang, X.-D., Francks, C., Thompson, P. M., & Kong, X. (2026) · Science Advances · doi:10.1126/sciadv.adu9309 · Cited by 4
Eshghi, M., Rong, P., Dadgostar, M., Shin, H., Richburg, B. D., Barnett, N. V., Salat, D. H., Arnold, S. E., & Green, J. R. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1740391 · Cited by 5
Structural And Computational Perspectives of Selectively Targeting Mutant Proteins
Coban, M., Fraga, S., & Caulfield, T. R. (2020) · Current Drug Discovery Technologies · doi:10.2174/1570163817666200311114819 · Cited by 4
Self-citationIsoform-Dependent Effects of Apolipoprotein E on Sphingolipid Metabolism in Neural Cells
Kurano, M., Tsukamoto, K., Sakai, E., Hara, M., & Yatomi, Y. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215205 · Cited by 5
Fray, S., Achouri-Rassas, A., Belal, S., & Messaoud, T. B. (2022) · Journal of Genetics · doi:10.1007/s12041-022-01384-9 · Cited by 4
Nazarian, A., Loiko, E., Yassine, H. N., Finch, C. E., & Kulminski, A. M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1023493 · Cited by 4
Akbarabadi, P., & Pourhosseini, P. S. (2022) · The Neuroscience Journal of Shefaye Khatam · doi:10.52547/shefa.11.1.105 · Cited by 4
Peripheral ApoE4 Leads to Cerebrovascular Dysfunction and Aβ Deposition in Alzheimer's Disease
Sun, R., & Xie, C. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01058-1 · Cited by 4
Cortical Amyloid Burden Relates to Basal Forebrain Volume in Subjective Cognitive Decline
Daamen, M., Scheef, L., Li, S., Grothe, M. J., Gaertner, F. C., Buchert, R., Büerger, K., Dobisch, L., Drzezga, A. E., Essler, M., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230141 · Cited by 4
LoBue, C., Stopschinski, B. E., Saez-Calveras, N., Douglas, P. M., Huebinger, R. M., Cullum, C. M., Hart, J., & Gonzales, M. M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-231027 · Cited by 4
Identification of immunogenic cell death-related genes involved in Alzheimer’s disease
Wang, R., Du, Y., Shao, W., Wang, J., Liu, X., Xu, X., Chen, G., & Sun, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-54357-6 · Cited by 5
Alzheimer’s Disease: A Suitable Case for Treatment with Precision Medicine?
Pauwels, E. K. J., & Boer, G. J. (2024) · Medical Principles and Practice · doi:10.1159/000538251 · Cited by 4
Calvo, C. D. B., & Bîndilă, L. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1450971 · Cited by 4
Metadata
- Authors
- Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G.
- Affiliations
- Mayo Clinic in Florida (US)
- Corresponding author
- Bu, Guojun
- Venue
- Nature Reviews Neurology
- Published
- 2019-07-31
- Volume
- 15
- Issue
- 9
- Pages
- 501-518
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC7055192
- OpenAlex
- W2965401191
- Cited by
- 1,425
- References
- 318
- Citations by year
- 2026: 191 · 2025: 259 · 2024: 233 · 2023: 242 · 2022: 200 · 2021: 172 · 2020: 124 · 2019: 4
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (RF1AG051504, R01AG027924, R37AG027924, RF1AG057181, RF1AG046205, R01AG035355)
- National Institute of Neurological Disorders and Stroke (P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE ε4, Alzheimer's disease, APOE polymorphism, amyloid-beta, tau pathology, neurodegeneration, microglial activation, lipid transport, synaptic plasticity, glucose metabolism, cerebrovascular function, precision medicine
- MeSH terms
- Alzheimer Disease, Apolipoproteins E, Brain, Humans, Polymorphism, Genetic, Amyloid beta-Peptides, Genetic Predisposition to Disease, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
